initiated. The primary end point in the PRIMO-CABG trial was "composite of death, myocardial infarction, or both at postoperative day 30 in patients undergoing coronary artery bypass grafting without valve surgery." The authors make the point that valve-CABG patients were not included in the primary population and therefore separate analysis of death and myocardial infarction of the 218 patients undergoing combined aortic valve replacement and CABG is permissible.
Another issue that arises from this study relates to the optimal selection of end points. The ideal end point is clinically relevant, objectively ascertained, and occurs at a sufficient frequency in the study population so as to allow the design of an adequately powered clinical trial without breaking the budget. Unfortunately, such end points rarely exist. The result is composite end points that often combine clinically significant or hard end points, which occur at a low frequency with less clinically important end points (soft end points), which are more common. Increasingly, surrogate end points consisting of biomarkers, functional assessments, or quality of life measurements are taking the place of or being combined with traditional hard clinical end points. In this study, the pre-specified composite end point consisted of all-cause mortality and myocardial infarction. Although a difference in mortality is unarguably of clinical importance, a difference in perioperative creatine kinase MB elevation is less so. In such situations in which the components of the composite end point carry unequal "weight," the differences in composite end points become more difficult to interpret. The optimal composite end point, therefore, would be one in which the components carry roughly equal clinical "weight," that is, are of equal clinical significance.
Furthermore, the end points need to be tailored to the patient population as well as the disease mechanism being studied. For example, when a drug that prevents ischemiareperfusion and inflammatory myocardial injury is being evaluated, myocardial infarction is a "cleaner" end point in patients undergoing isolated valve surgery; that is, it is not confounded by other determinants of myocardial infarction like extent and diffuseness of coronary disease, types of grafts used, or history of myocardial infarction. In a group of patients undergoing CABG in addition to valve surgery, these and other confounders that can affect the rates of perioperative myocardial injury may not be equally distributed among the treatment and control groups, particularly when the sample size is relatively small. In the present study, there are statistically nonsignificant but potentially important differences in New York Heart Association class status, prior myocardial infarction, and number of grafts per patient. In addition, certain other patient-and diseaserelated variables that are not reported or measured may differ between groups. This, again, reinforces the need to pre-specify the subgroups and end points that are to be analyzed at the design stage, ensuring that a large enough sample size exists to allow the results of these subgroup analyses to be meaningful and generalizable.
Finally, the question must be raised as to whether such a drug is necessary to improve the outcome of patients after complex cardiac operations during which time the patient is subjected to cardiopulmonary bypass. For most low-risk cardiac procedures, patients will not likely benefit. However, for very ill patients undergoing prolonged, complicated operations, selective inhibition of complement may improve the outcome, as demonstrated in the present study. In these days when hospital administrators keep track of costs of doing cardiac surgery, the cost of pexelizumab will no doubt affect how often it is administered. Clearly not everyone will receive it at even a modest incremental cost, but at very high cost, very few will receive the drug. The efficacy, as determined by the results of the recently completed PRIMO-CABG II trial, in which additional patients were enrolled, and the cost of the drug, will determine the place of pexelizumab in the treatment of patients having cardiac surgery and in the market.
